Among stage III patients, Gettinger and colleagues observed survival benefit associated with tumor-infiltrating lymphocytes, in addition to a survival benefit upon treatment with immune checkpoint blockers, irrespective of tumor mutational load and PD-1 expression47. The gene discussed is PDCD1; the disease is neoplasm.